Charles River Laboratories International, Inc. (NYSE:CRL) Receives $256.38 Average PT from Analysts

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have earned a consensus recommendation of “Moderate Buy” from the fourteen brokerages that are currently covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $254.50.

Several research firms recently weighed in on CRL. Robert W. Baird dropped their price objective on shares of Charles River Laboratories International from $282.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, May 10th. Argus reiterated a “hold” rating on shares of Charles River Laboratories International in a research note on Friday, June 28th. The Goldman Sachs Group began coverage on shares of Charles River Laboratories International in a research note on Thursday, June 6th. They set a “buy” rating and a $290.00 price objective on the stock. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday, June 14th. Finally, Barclays initiated coverage on shares of Charles River Laboratories International in a research note on Friday, June 28th. They set an “equal weight” rating and a $230.00 price objective on the stock.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock opened at $201.42 on Thursday. The firm has a market cap of $10.38 billion, a PE ratio of 23.70, a price-to-earnings-growth ratio of 1.95 and a beta of 1.38. The firm’s 50-day simple moving average is $218.04 and its 200-day simple moving average is $232.13. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.37 and a current ratio of 1.75. Charles River Laboratories International has a 1 year low of $161.65 and a 1 year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, topping the consensus estimate of $2.05 by $0.22. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. Equities analysts forecast that Charles River Laboratories International will post 11 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Joseph W. Laplume sold 1,304 shares of the stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $226.97, for a total value of $295,968.88. Following the completion of the transaction, the executive vice president now directly owns 23,276 shares in the company, valued at $5,282,953.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Czech National Bank grew its position in Charles River Laboratories International by 0.5% in the 1st quarter. Czech National Bank now owns 9,025 shares of the medical research company’s stock worth $2,445,000 after purchasing an additional 41 shares during the last quarter. Cardinal Capital Management grew its position in Charles River Laboratories International by 0.6% in the 4th quarter. Cardinal Capital Management now owns 8,450 shares of the medical research company’s stock worth $1,998,000 after purchasing an additional 47 shares during the last quarter. Massmutual Trust Co. FSB ADV grew its position in Charles River Laboratories International by 21.5% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 328 shares of the medical research company’s stock worth $78,000 after purchasing an additional 58 shares during the last quarter. Patriot Financial Group Insurance Agency LLC grew its position in Charles River Laboratories International by 5.7% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 1,126 shares of the medical research company’s stock worth $266,000 after purchasing an additional 61 shares during the last quarter. Finally, Dumont & Blake Investment Advisors LLC grew its position in Charles River Laboratories International by 1.4% in the 1st quarter. Dumont & Blake Investment Advisors LLC now owns 4,415 shares of the medical research company’s stock worth $1,196,000 after purchasing an additional 62 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).